FDA's Approach to Regulation of Products of Nanotechnology

被引：95

作者：

Hamburg, Margaret A. ^{[1
]}

机构：

[1] US FDA, Silver Spring, MD 20993 USA

来源：

SCIENCE | 2012年 / 336卷 / 6079期

关键词：

D O I：

10.1126/science.1205441

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];

摘要：

A broadly inclusive initial approach may become more nuanced in light of experience, scientific information, and public input.

引用

页码：299 / 300

页数：2

共 13 条

[1]

[Anonymous], 2001, WHATS SO SPEC NAN

[2]

EC, REC DEF NAN

[3]

FDA, CONS WHETH FDA REG P

[4]

FDA, NAN REG SCI RES CAT

[5]

Health Canada, 2011, Policy Statement on Health Canada's Working Definition for Nanomaterial-Canada.ca

[6]

Holdren J.P., 2011, Policy principles for the U.S. decision-making concerning regulation and oversight of applications of nanotechnology and nanomaterials

[7]

Nanosizing - Oral formulation development and biopharmaceutical evaluation [J].

Kesisoglou, Filippos ;

Panmai, Santipharp ;

Wu, Yunhui .

ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :631-644

[8]

Lovestam G., 2010, Considerations on a definition of nanomaterial for regulatory purposes

[9]

Nanomedicine: current status and future prospects [J].

Moghimi, SM ;

Hunter, AC ;

Murray, JC .

FASEB JOURNAL, 2005, 19 (03) :311-330

[10]

NNI, 2010, CAPST M RISK MAN MET

← 1 2 →